Long Term outcomes of percutaneous atrial fibrillation ablation in patients with continuous monitoring.
Atrial fibrillation
ablation
cardiac implantable device
continuous monitoring
Journal
Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
09
05
2021
received:
19
11
2020
accepted:
16
05
2021
pubmed:
25
5
2021
medline:
19
2
2022
entrez:
24
5
2021
Statut:
ppublish
Résumé
There is limited data using continuous monitoring to assess outcomes of atrial fibrillation (AF) ablation. This study assessed long-term outcomes of AF ablation in patients with implantable cardiac devices. 207 patients (mean age 68.1 ± 9.5, 50.3% men) undergoing ablation for symptomatic AF were followed up for a mean period of 924.5 ± 636.7 days. Techniques included The Pulmonary Vein Ablation Catheter (PVAC) (59.4%), cryoablation (17.4%), point by point (14.0%) and The Novel Irrigated Multipolar Radiofrequency Ablation Catheter (nMARQ) (9.2%). 130 (62.8%) patients had paroxysmal AF (PAF) and 77 (37.2%) persistent AF. First ablation and repeat ablation reduced AF burden significantly (relative risk 0.91, [95% CI 0.89 to 0.94]; P <0.0001 and 0.90, [95% CI, 0.86-0.94]; P <0.0001). Median AF burden in PAF patients reduced from 1.05% (interquartile range [IQR], 0.1%-8.70%) to 0.10% ([IQR], 0%-2.28%) at one year and this was maintained out to four-years. Persistent AF burden reduced from 99.9% ([IQR], 51.53%-100%) to 0.30% ([IQR], 0%-77.25%) at one year increasing to 87.3% ([IQR], 4.25%-100%) after four years. If a second ablation was required, point-by-point ablation achieved greater reduction in AF burden (relative risk, 0.77 [95% CI, 0.65-0.91]; P <0.01). Ablation reduces AF burden both acutely and in the long-term. If a second ablation was required the point-by-point technique achieved greater reductions in AF burden than "single-shot" technologies. Persistent AF burden increased to near pre ablation levels by year 4 suggesting a different mechanism from PAF patients where this increase did not occur.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1176-1184Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fbrillation: European perspective. Clin Epidemiol. 2014;6(1):213-20.
Kirchhof P, Benussi S, Zamorano JL, Aboyans V, Achenbach S, Agewall S, et al. ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Vol. 147, Russian Journal of Cardiology. 2017. p. 7-86.
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R. J Am Coll Cardiol. 2019;74(1):104-32.
Kuck KH, Brugada J, Fürnkranz A, Metzner A, Ouyang F, Chun KRJ, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235-45.
Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2) a randomized trial. JAMA - J Am Med Assoc. 2014;311(7):692-9.
Dinshaw L, Schäffer B, Akbulak Ö, Jularic M, Hartmann J, Klatt N, et al. Long-term efficacy and safety of radiofrequency catheter ablation of atrial fibrillation in patients with cardiac implantable electronic devices and transvenous leads. J Cardiovasc Electrophysiol. 2019.
Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Vol. 2, Journal of the American Heart Association. 2013.
Stiles MK, Sanders P, Lau DH. Targeting the substrate in ablation of persistent atrial fibrillation: Recent lessons and future directions. Vol. 9, Frontiers in Physiology. 2018.
Andrade JG, Champagne J, Dubuc M, Deyell MW, Verma A, Macle L, et al. Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial. Circulation [Internet]. 2019;140:1779-88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31630538
BjÖrkenheim A, Brandes A, Chemnitz A, Magnuson A, Edvardsson N, PoÇi D. Rhythm Control and Its Relation to Symptoms during the First Two Years after Radiofrequency Ablation for Atrial Fibrillation. PACE - Pacing Clin Electrophysiol. 2016;39(9):914-25.
Haïssaguerre M, Wright M, Hocini M, Jaïs P. The substrate maintaining persistent atrial fibrillation. Vol. 1, Circulation. Arrhythmia and electrophysiology. 2008. p. 2-5.
Terricabras M, Piccini JP, Verma A. Ablation of persistent atrial fibrillation: Challenges and solutions. Vol. 31, Journal of Cardiovascular Electrophysiology. 2020. p. 1809-21.
Hussein A, Das M, Riva S, Morgan M, Ronayne C, Sahni A, et al. Use of Ablation Index-Guided Ablation Results in High Rates of Durable Pulmonary Vein Isolation and Freedom From Arrhythmia in Persistent Atrial Fibrillation Patients. Circ Arrhythm Electrophysiol. 2018;11(9):e006576.
Valderrábano M, Peterson LE, Swarup V, Schurmann PA, Makkar A, Doshi RN, et al. Effect of Catheter Ablation with Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial. JAMA - J Am Med Assoc. 2020;324(16):1620-8.
Martinek M, Aichinger J, Nesser HJ, Ziegler PD, Purerfellner H. New insights into long-term follow-up of atrial fibrillation ablation: Full disclosure by an implantable pacemaker device. J Cardiovasc Electrophysiol. 2007;18(8):818-23.
Choudhury R, Coutino HE, Darciuc R, Ströker E, De Regibus V, Mugnai G, et al. Continuous monitoring after second-generation cryoballoon ablation for paroxysmal atrial fibrillation in patients with cardiac implantable electronic devices. Hear Rhythm. 2019;16(2):187-96.
Wechselberger S, Kronborg M, Huo Y, Piorkowski J, Neudeck S, Päßler E, et al. Continuous monitoring after atrial fibrillation ablation: the LINQ AF study. Europace. 2018;20(FI3):f312-20.
Buist TJ, Adiyaman A, Smit JJJ, Ramdat Misier AR, Elvan A. Arrhythmia-free survival and pulmonary vein reconnection patterns after second-generation cryoballoon and contact-force radiofrequency pulmonary vein isolation. Clin Res Cardiol. 2018;107(6):498-506.
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417-27.